Recap: Repare Therapeutics Q3 Earnings
Portfolio Pulse from Benzinga Insights
Repare Therapeutics (NASDAQ:RPTX) reported its Q3 earnings, beating estimated earnings by 47.67% with an EPS of $-0.45 versus an estimate of $-0.86. However, revenue was down $110.39 million from the same period last year. Last quarter, the company beat on EPS by $0.5, which was followed by a 17.1% increase in the share price the next day.
November 09, 2023 | 12:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Repare Therapeutics beat Q3 earnings estimates but reported a significant drop in revenue compared to the same period last year. Past performance shows a positive correlation between beating EPS estimates and share price increase.
Repare Therapeutics has a history of share price increase following beating EPS estimates. Despite the drop in revenue, the significant beat on earnings could potentially lead to a short-term increase in share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100